MA52662A - Conjugués d'il-2 - Google Patents
Conjugués d'il-2Info
- Publication number
- MA52662A MA52662A MA052662A MA52662A MA52662A MA 52662 A MA52662 A MA 52662A MA 052662 A MA052662 A MA 052662A MA 52662 A MA52662 A MA 52662A MA 52662 A MA52662 A MA 52662A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18164682 | 2018-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52662A true MA52662A (fr) | 2021-02-17 |
Family
ID=61832449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052662A MA52662A (fr) | 2018-03-28 | 2019-03-27 | Conjugués d'il-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210024602A1 (fr) |
| EP (1) | EP3773680A1 (fr) |
| JP (2) | JP7490563B2 (fr) |
| KR (1) | KR20200139730A (fr) |
| CN (1) | CN111918665A (fr) |
| AU (1) | AU2019246389B2 (fr) |
| BR (1) | BR112020019639A2 (fr) |
| CA (1) | CA3093722A1 (fr) |
| IL (2) | IL308797A (fr) |
| MA (1) | MA52662A (fr) |
| MX (1) | MX2020009857A (fr) |
| SG (1) | SG11202007524QA (fr) |
| WO (1) | WO2019185705A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3071013A1 (fr) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | Conjugues de cytokine destines au traitement de maladies proliferatives et infectieuses |
| AU2020204785A1 (en) | 2019-01-04 | 2021-06-03 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
| AU2020204970A1 (en) | 2019-01-04 | 2021-06-24 | Ascendis Pharma Oncology Division A/S | Conjugates of pattern recognition receptor agonists |
| US20220054478A1 (en) | 2019-01-04 | 2022-02-24 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| EP3986479A1 (fr) | 2019-06-21 | 2022-04-27 | Ascendis Pharma Oncology Division A/S | Conjugués anti-ctla4 |
| BR112022011513A2 (pt) * | 2019-12-13 | 2022-08-23 | Synthekine Inc | Ortólogos de il-2 e métodos de uso |
| CN114478743A (zh) * | 2019-12-17 | 2022-05-13 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| CR20220530A (es) | 2020-04-22 | 2022-12-15 | Merck Sharp & Dohme Llc | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß¿c Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO. |
| KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
| US20230340055A1 (en) | 2020-08-28 | 2023-10-26 | Ascendis Pharma Oncology Division A/S | Glycosylated il-2 proteins and uses thereof |
| EP4384204A1 (fr) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Combinaison d'agonistes de l'il-2/il-15rbetagamma avec des conjugués anticorps-médicament pour le traitement du cancer |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| EP1353701B1 (fr) | 2000-10-31 | 2011-12-21 | PR Pharmaceuticals, Inc. | Methodes de production de compositions pour ameliorer l'administration de molecules bioactives |
| US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| CA2521784C (fr) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Medicaments pegyles reversibles |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| BR122019021416A2 (fr) | 2003-09-19 | 2019-12-21 | ||
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| AU2005227263A1 (en) | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| WO2005099768A2 (fr) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Lieur de promedicaments |
| SG158148A1 (en) | 2004-12-22 | 2010-01-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| WO2008034122A2 (fr) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides |
| DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
| EP2175878A4 (fr) | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | Système d'administration de médicament polymérique contenant un groupement aromatique multi-substitué |
| ES2904673T3 (es) | 2008-02-01 | 2022-04-05 | Ascendis Pharma As | Profármaco que comprende un conjugado de fármaco-enlazador. |
| CN102989001B (zh) * | 2008-04-29 | 2014-12-03 | 阿森迪斯药物生长障碍股份有限公司 | Peg化的重组人生长激素化合物 |
| WO2009143412A2 (fr) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d’oligonucléotides |
| LT2393828T (lt) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos |
| SG177761A1 (en) | 2009-07-31 | 2012-03-29 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| RU2012129674A (ru) * | 2009-12-15 | 2014-01-27 | Аспендис Фарма Ас | Композиция гормона роста |
| CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
| US9561285B2 (en) * | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| EP2566334B1 (fr) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Supports solides pour la libération contrôlée de médicaments |
| PL2571510T3 (pl) | 2010-05-21 | 2019-03-29 | Xl-Protein Gmbh | Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania |
| JP5594791B2 (ja) | 2010-06-30 | 2014-09-24 | Ｎｅｃソリューションイノベータ株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
| CA3144697A1 (fr) * | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugues d'une fraction il-2 et d'un polymere |
| MY190604A (en) | 2011-02-10 | 2022-04-27 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| US20140243254A1 (en) | 2011-08-12 | 2014-08-28 | Ascendis Pharma A/S | Polymeric Hyperbranched Carrier-Linked Prodrugs |
| JP6041314B2 (ja) * | 2011-08-31 | 2016-12-07 | 国立大学法人三重大学 | がん治療用ワクチン製剤 |
| WO2013036857A1 (fr) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Coupleurs au sulfone |
| CA2884910C (fr) | 2012-10-11 | 2021-07-13 | Ascendis Pharma Ophthalmology Division A/S | Pro-medicaments de neutralisation de vegf pour le traitement d'etats oculaires |
| AU2013328785B2 (en) | 2012-10-11 | 2016-07-21 | Ascendis Pharma A/S | Hydrogel prodrugs |
| JP2015536314A (ja) | 2012-10-17 | 2015-12-21 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン送達のための脂肪酸アシル化アミノ酸 |
| CA2925421C (fr) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Proteines hybrides de l'interleukine-2 et leurs utilisations |
| PL3134123T3 (pl) * | 2014-02-21 | 2021-07-12 | Nektar Therapeutics (India) Pvt. Ltd. | Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1 |
| EP3193941B1 (fr) | 2014-08-06 | 2024-05-22 | Ascendis Pharma A/S | Promédicaments comprenant un liant de type aminoalkylglycine |
| EA034925B1 (ru) | 2014-08-11 | 2020-04-07 | Делиниа, Инк. | Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний |
| RS61734B2 (sr) * | 2014-11-18 | 2022-04-29 | Ascendis Pharma Endocrinology Div A/S | Novi polimerni hgh pro-lekovi |
| US10835578B2 (en) * | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| CN115025239A (zh) | 2016-03-01 | 2022-09-09 | 阿森迪斯药物骨疾病股份有限公司 | Pth前药 |
| EP3518982A1 (fr) * | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases A/S | Schéma posologique incrémentiel dans des composés de pth à libération contrôlée |
| CA3055985A1 (fr) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Compositions de promedicament d'hydrogel d'acide hyaluronique reticule et procedes |
| WO2019185706A1 (fr) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugués |
-
2019
- 2019-03-27 EP EP19713040.4A patent/EP3773680A1/fr active Pending
- 2019-03-27 WO PCT/EP2019/057709 patent/WO2019185705A1/fr unknown
- 2019-03-27 IL IL308797A patent/IL308797A/en unknown
- 2019-03-27 JP JP2020552812A patent/JP7490563B2/ja active Active
- 2019-03-27 MX MX2020009857A patent/MX2020009857A/es unknown
- 2019-03-27 US US17/042,610 patent/US20210024602A1/en active Pending
- 2019-03-27 MA MA052662A patent/MA52662A/fr unknown
- 2019-03-27 AU AU2019246389A patent/AU2019246389B2/en active Active
- 2019-03-27 BR BR112020019639-8A patent/BR112020019639A2/pt unknown
- 2019-03-27 CA CA3093722A patent/CA3093722A1/fr active Pending
- 2019-03-27 CN CN201980022172.XA patent/CN111918665A/zh active Pending
- 2019-03-27 KR KR1020207031136A patent/KR20200139730A/ko not_active Application Discontinuation
- 2019-03-27 SG SG11202007524QA patent/SG11202007524QA/en unknown
- 2019-03-27 IL IL277572A patent/IL277572B2/en unknown
-
2024
- 2024-02-22 JP JP2024025984A patent/JP2024073467A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277572B2 (en) | 2024-05-01 |
| CN111918665A (zh) | 2020-11-10 |
| SG11202007524QA (en) | 2020-09-29 |
| JP2024073467A (ja) | 2024-05-29 |
| AU2019246389A1 (en) | 2020-08-27 |
| JP2021519336A (ja) | 2021-08-10 |
| JP7490563B2 (ja) | 2024-05-27 |
| IL308797A (en) | 2024-01-01 |
| EP3773680A1 (fr) | 2021-02-17 |
| IL277572A (en) | 2020-11-30 |
| MX2020009857A (es) | 2021-01-08 |
| AU2019246389B2 (en) | 2024-08-22 |
| BR112020019639A2 (pt) | 2021-01-05 |
| US20210024602A1 (en) | 2021-01-28 |
| IL277572B1 (en) | 2024-01-01 |
| WO2019185705A1 (fr) | 2019-10-03 |
| KR20200139730A (ko) | 2020-12-14 |
| CA3093722A1 (fr) | 2019-10-03 |
| RU2020135268A (ru) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52662A (fr) | Conjugués d'il-2 | |
| MA52669A (fr) | Conjugués peptidiques de camptothécine | |
| DK3592393T3 (da) | Frigørbare konjugater | |
| DK3946464T3 (da) | Forbindelser og konjugater deraf | |
| DK3794042T3 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| MA51778A (fr) | Conjugués anticorps-médicament anti-ccr7 | |
| UA42295S (uk) | Комп'ютер | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| DK3584189T3 (da) | Fastgjort bindeledslåg | |
| UA42369S (uk) | Комп'ютер | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA51157A (fr) | Récepteurs de l'interleukine darique | |
| JP2020012785A5 (fr) | ||
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| DK3911298T3 (da) | Formuleringer | |
| IT201700035964A1 (it) | “divisorio per boiserie” | |
| ES1261716Y (es) | "cubrecajas" | |
| IT201900020679A1 (it) | Giunzione regolabile | |
| UA41328S (uk) | Стільниця | |
| UA37871S (uk) | Ювелірна прикраса-сережки «клюшка» | |
| UA37874S (uk) | Ювелірна прикраса-чокер «клюшка» | |
| UA36802S (uk) | Стіл учнівський | |
| UA39879S (uk) | Стільниця | |
| IT201800009293A1 (it) | "divano" | |
| JP1641265S (ja) | 机 |